Harshita Aggarwal
It is especially crucial to develop ways to acquire molecules with meaningful diagnostic effects due to the high prevalence and mortality of Colorectal Cancer (CRC) and the absence of effective diagnostic molecules, which have resulted in poor treatment outcomes for colorectal cancer. To uncover individual and co-pathways of change in early-stage and colorectal malignancies and to learn the factors that contribute to the development of colorectal cancer, we proposed a whole and part study strategy (early-stage colorectal cancer as "part" and colorectal cancer as "whole"). The pathological state of tumour tissue may not always be reflected by metabolite indicators found in plasma. Multi-omics analyses of 128 plasma metabolomes and 84 tissue transcriptomes were conducted on three phases of biomarker discovery research (discovery, identification, and validation) in order to investigate the determining biomarkers linked to plasma and tumour tissue in the course of CRC. Importantly, we note that patients with colorectal cancer had much greater metabolic levels of oleic acid and FA than did healthy individuals. Oleic acid and FA (18:2) can both stimulate the growth of colorectal cancer tumour cells and serve as plasma biomarkers for the early stages of the disease, according to biofunctional verification. Our work offers a promising tool for the clinical detection of colorectal cancer, and we suggest a unique research approach to identify co-pathways and significant biomarkers that may be targeted for a possible role in early colorectal cancer.
